Ligand Pharmaceuticals Incorporated (LGND)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.18B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ligand Pharmaceuticals Incorporated (LGND) P/E Ratio & Valuation History
Ligand Pharmaceuticals (LGND) trades at 66.5x trailing earnings and 23.7x sales. Its P/E of 66.5x is above its 5-year median of 17.9x. Its forward P/E is 25.1x. The median P/E across 3 similar companies is 87.2x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 164.9% higher over the next year. Its free cash flow yield is 1.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 66.5x |
| Forward P/E | 25.1x |
| Price to sales | 23.7x |
| Price to book | 6.3x |
| EV/EBITDA | 189.1x |
| Price to FCF | 66.5x |
| EV/FCF | 78.3x |
| PEG | 1.5 |
| FCF yield | 1.5% |
Historical Medians
Against its 10-year medians, its P/E is 179.4% above 23.8x, its P/S is 76.9% above 13.4x and its P/B is 142.3% above 2.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 66.5x | 17.9x | 23.8x |
| P/S | 23.7x | 10.7x | 13.4x |
| P/B | 6.3x | 2.4x | 2.6x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 11.7x in 2023 to 42.3x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $189.07 | 27.9x | 14.0x | 3.9x |
| 2024 | $107.15 | 18.8x | 11.7x | 2.4x |
| 2023 | $71.42 | 11.7x | 9.4x | 1.8x |
| 2022 | $66.80 | 15.0x | 5.7x | 1.9x |
| 2021 | $154.46 | 24.1x | 10.6x | 3.1x |
| 2020 | $99.45 | 21.9x | 9.9x | 2.3x |
| 2019 | $104.29 | 34.3x | 16.6x | 2.3x |
| 2018 | $135.70 | 19.0x | N/A | 5.1x |
| 2017 | $136.93 | 42.3x | 20.4x | 6.9x |
| 2016 | $101.61 | 30.4x | 19.4x | 5.7x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LGND
What is LGND's forward P/E ratio?
Ligand Pharmaceuticals has a forward P/E ratio of 25.1x.
Is LGND stock overvalued?
GNG's valuation label for LGND is Overvalued. Its P/E of 66.5x compares with a median of 87.2x across 3 similar companies.
What is LGND's price to sales ratio?
Ligand Pharmaceuticals has a price to sales ratio of 23.7x.
What is Ligand Pharmaceuticals's average P/E ratio over 5 years?
Ligand Pharmaceuticals's median P/E over the last 5 years is 17.9x, from 60 month-end values through Oct 2026.
What is LGND's PEG ratio?
Ligand Pharmaceuticals has a PEG ratio of 1.5.
LGND pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors